Effect of administration of zinc supplementation on lipid profile and uric acid in smokers and non-smokers

Not Applicable

Completed

• Conditions: zinc deficiency; hyperlipidemia; Cardiovascular - Other cardiovascular diseases; hyperurecemia; Mental Health - Addiction

• Registration Number: ACTRN12622000549729
• Lead Sponsor: Dr. Malik Hassan Mehmood

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-04-08
• Study Completion: 2022-08-16
• Last Update Posted: 12 September 2022

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 75

Inclusion Criteria

1)Volunteers age range between 18 to 60 years
2)Only healthy volunteers were included in control group
3)Smoker must use 5 cigarettes per day from last 2 years
4)Participants must not receiving prescribed medication like as lipid lowering agents (fibrins, statins) and uric acid lowering agents (allopurinol) which might interfere with study protocol.
5)Participants included in experimental group were not having the history of some chronic cardiovascular disease, respiratory disease, diabetes mellitus, hepatic or renal disorder or any other severe disease.

Exclusion Criteria

1)Female volunteers if pregnant, lactating or using contraceptive were excluded from the study.
2)Smokers under nicotine dependence treatment from last three months were excluded from the study.
3)Persons with decrease lipid profile, uric acid levels and normal level of plasma zinc were not participating in study.
4)Participants who were recently consuming supplements in the past three months were excluded from study
5)Persons with alcohol consumption history were not participated in study.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
lipid profile test include low density lipo-protein(LDL), high density lipo-protein(HDL), total cholestrol (TC), triglycerides (TG) (unit=mg/dl)<br><br>To be assessed through an independent laboratory. Blood sample will be collected by a person not involved in study, in a vacutainer containing Clotting-Activator gel. Necessary measures will be taken to control conditions to preserve sample.[First at time of recruitment<br>After 8 weeks from start of intervention];serum uric acid level<br><br>To be assessed through an independent laboratory. Blood sample will be collected by a person not involved in study, Necessary measures will be taken to control conditions to preserve sample.[First at the time of recruitment at zero day, then After 60 days (8 weeks) from the start of the intervention,<br>]

Secondary Outcome Measures

Name	Time	Method
migraine attack severity checked by self structured questionnaire [First at time of recruitment through pre-questionnaire <br>After 8 weeks from start of intervention through post-questionnaire ];serum zinc test.<br>[First at time of recruitment at zero day then After 60 days/ 8 weeks from start of intervention<br>]